AUROBINDO PHARMA |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,242 INR | -1.79% |
|
+1.11% | +14.49% |
| Jun. 05 | Hindalco-owned Novelis delays US IPO; shares slide | RE |
| May. 27 | Aurobindo Pharma Clocks Gains in Fiscal Q4 Consolidated Net Profit | MT |
| Sales 2024 | 290B 3.47B | Sales 2025 * | 317B 3.79B | Capitalization | 741B 8.88B |
|---|---|---|---|---|---|
| Net income 2024 | 31.73B 380M | Net income 2025 * | 39.08B 468M | EV / Sales 2024 | 2.2 x |
| Net cash position 2024 * | 18.34B 220M | Net cash position 2025 * | 24.56B 294M | EV / Sales 2025 * | 2.26 x |
| P/E ratio 2024 |
20.1
x | P/E ratio 2025 * |
19
x | Employees | 23,451 |
| Yield 2024 * |
0.33% | Yield 2025 * |
0.39% | Free-Float | 47.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aurobindo Pharma
More recommendations
More press releases
More news
| 1 day | -1.90% | ||
| 1 week | +1.11% | ||
| Current month | +4.67% | ||
| 1 month | +10.07% | ||
| 3 months | +16.56% | ||
| 6 months | +23.56% | ||
| Current year | +14.49% |
1 week
1 109.45
1 292.10
1 month
1 109.451 292.10
Current year
958.501 292.10
1 year
661.101 292.10
3 years
397.201 292.10
5 years
288.851 292.10
10 years
288.851 292.10
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 66 | 86-12-25 | |
| Director of Finance/CFO | - | 12-12-31 | |
B. Adi Reddy
CMP | Compliance Officer | - | 16-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 66 | 86-12-25 | |
| Founder | 66 | 86-12-25 | |
| Director/Board Member | 64 | 03-05-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.32% | 6 M€ | +6.07% | - | |
| 0.22% | 21 M€ | +7.05% | ||
| 0.12% | 11 M€ | +4.31% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 1,242 | -1.79% | 1 265 090 |
| 24-06-07 | 1,265 | +1.11% | 1,879,997 |
| 24-06-06 | 1,251 | -1.19% | 1,165,617 |
| 24-06-05 | 1,266 | +5.77% | 1,565,785 |
| 24-06-04 | 1,197 | -2.45% | 1,434,945 |
Delayed Quote NSE India S.E., June 10, 2024 at 03:42 am EDT
More quotes
Aurobindo Pharma specializes in the research, development, manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The group's activity is organized around 2 product families :
- generic drugs: for the treatment of neurological, cardiovascular, viral, gastroenterological, ophthalmologic and chronic diseases;
- active pharmaceutical ingredients.
At the end of March 2018, the group operated 23 production sites in India (19), the United States (3) and Brazil.
Net sales are distributed geographically as follows: India (12%), the United States (46.5%), Europe (31.2%) and other (10.3%).
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,265
INR
Average target price
1,295
INR
Spread / Average Target
+2.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.49% | 8.88B | |
| +45.82% | 765B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.92% | 248B | |
| -0.98% | 219B | |
| +11.29% | 216B | |
| +5.90% | 164B | |
| -0.73% | 162B |
- Stock Market
- Equities
- AUROPHARMA Stock
